Nishio K - Search Results

1

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.

Hata A, Katakami N, Takase N, Kibata K, Yamanaka Y, Tamiya M, Mori M, Kijima T, Morita S, Sakai K, Nishio K. Hata A, et al. Among authors: nishio k. Lung Cancer. 2024 Nov;197:107988. doi: 10.1016/j.lungcan.2024.107988. Epub 2024 Oct 5. Lung Cancer. 2024. PMID: 39393258 Clinical Trial.

2

Establishment of a CPT-11-resistant human ovarian cancer cell line.

Kijima T, Kubota N, Nishio K. Kijima T, et al. Among authors: nishio k. Anticancer Res. 1994 May-Jun;14(3A):799-803. Anticancer Res. 1994. PMID: 8074481

3

Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.

Nomoto T, Nishio K, Ishida T, Mori M, Saijo N. Nomoto T, et al. Among authors: nishio k. Jpn J Cancer Res. 1998 Nov;89(11):1179-86. doi: 10.1111/j.1349-7006.1998.tb00513.x. Jpn J Cancer Res. 1998. PMID: 9914787 Free PMC article.

4

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

Kimura H, Kasahara K, Sekijima M, Tamura T, Nishio K. Kimura H, et al. Among authors: nishio k. Lung Cancer. 2005 Dec;50(3):393-9. doi: 10.1016/j.lungcan.2005.07.012. Epub 2005 Sep 8. Lung Cancer. 2005. PMID: 16153743

5

Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.

Sakai K, Arao T, Shimoyama T, Murofushi K, Sekijima M, Kaji N, Tamura T, Saijo N, Nishio K. Sakai K, et al. Among authors: nishio k. FASEB J. 2006 Feb;20(2):311-3. doi: 10.1096/fj.05-4034fje. Epub 2005 Dec 22. FASEB J. 2006. PMID: 16373402

6

In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.

Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. Sakai K, et al. Among authors: nishio k. Biochem J. 2006 Aug 1;397(3):537-43. doi: 10.1042/BJ20051962. Biochem J. 2006. PMID: 16623663 Free PMC article.

7

Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.

Shimoyama T, Koizumi F, Fukumoto H, Kiura K, Tanimoto M, Saijo N, Nishio K. Shimoyama T, et al. Among authors: nishio k. Lung Cancer. 2006 Jul;53(1):13-21. doi: 10.1016/j.lungcan.2006.03.014. Epub 2006 May 19. Lung Cancer. 2006. PMID: 16713012

8

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.

Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Kimura H, et al. Among authors: nishio k. Cancer Sci. 2007 Aug;98(8):1275-80. doi: 10.1111/j.1349-7006.2007.00510.x. Epub 2007 May 13. Cancer Sci. 2007. PMID: 17498200 Free PMC article.

9

Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation.

Morinaga R, Okamoto I, Furuta K, Kawano Y, Sekijima M, Dote K, Satou T, Nishio K, Fukuoka M, Nakagawa K. Morinaga R, et al. Among authors: nishio k. Lung Cancer. 2007 Dec;58(3):411-3. doi: 10.1016/j.lungcan.2007.05.014. Epub 2007 Jun 29. Lung Cancer. 2007. PMID: 17601631

10

Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.

Sakai K, Yokote H, Murakami-Murofushi K, Tamura T, Saijo N, Nishio K. Sakai K, et al. Among authors: nishio k. Cancer Sci. 2007 Sep;98(9):1498-503. doi: 10.1111/j.1349-7006.2007.00553.x. Epub 2007 Jul 11. Cancer Sci. 2007. PMID: 17627612 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,213 results

Search Page

Filters